Summary of Solid Pharmaceuticals Evaluated for Radical Production by Electron Paramagnetic Resonance (EPR)
Investigation Methods | Substances | Indication | Radiation Conditions | Observations |
---|---|---|---|---|
EPR (49) | Aminoglutethimide | Anti-steroid | Microcrystalline powder form, 10 and 20 kGy at 5 kGy/h with EPR 4/8 wks after irradiation |
|
Azathioprine | Immunosuppressive | |||
Clozapine | Antipsychotic | |||
Flutamide | Non-steroidal antiandrogen | |||
Ifosfamide | Chemotherapy | |||
Indobufen | Platelet aggregation inhibitor | |||
Ketoconazole | Antifungal | |||
Mercaptopurine | Immunosuppressive | |||
Mesalazine | Anti-inflammatory | |||
Metronidazole | Antibiotic | |||
Nifedipine | Calcium channel blocker | |||
Nimodipine | Calcium channel blocker | |||
Nitrendipine | Calcium channel blocker | |||
Ornidazole | Antiamoebic | |||
Tamoxifen Citrate | Estrogen receptor antagonist | |||
EPR (50) | Cilazapril | ACE Inhibitor | 1–20 kGy, EPR measurement performed several times over 2 years |
|
Diltiazem HCl | Hypertension | |||
Doxazosin Mesylate | α1-Selective alpha blocker | |||
Enalapril Maleate | ACE Inhibitor | |||
Lisinopril | ACE Inhibitor | |||
Pentoxifylline | Intermittent claudication | |||
Pergolide Mesylate | Dopamine receptor agonist | |||
Selegiline | Parkinson's Disease | |||
Sodium Valproate | Anticonvulsant | |||
EPR (51) | Felodipine | Calcium channel blocker | Powders irradiated at room temperature to 20 kGy dose at 1.02 Gy/h, EPR evaluated with stability samples (9 months) |
|
Nifedipine | ||||
Nimodipine | ||||
Nitrendipine |